Description
Mesterolone (Provimed) is dosed at 25 mg per tablet. It is not an anabolic but a very powerful anti-estrogen. Prevents gynecomastia, while reducing water and fat retention, it allows the relaunch of deem testosterone production in the testicles, while preventing the aromatization of anabolics.
Provimed acts as an anti-aromatic: it prevents the aromatization (transformation) of anabolic steroids into estrogens. It thus avoids gynecomastia. It can be combined with Nolvadex to increase its effectiveness. It should indeed be specified that Provimed and Nolvadex are two anti-oestrogens whose mechanisms of action are different and complementary, and it is for this reason that the combination of these two products is so effective: while Provimed prevents the aromatizing anabolic, Nolvadex clogs estrogen receptor cells, preventing it from working. It is therefore a formidable tandem.
Provimed is also not only an excellent anti-estrogen : by maintaining a low level of estrogen, Provimed also reduces water retention. It thus gives the user the skinned look sought after by so many bodybuilders, especially when preparing for competitions.
It should be noted that Provimed tends to limit muscle gains from a steroid cycle, because it attaches to androgen receptor cells instead of other steroids present in the body, which then remain blocked outside. and therefore without effect. This is why many bodybuilders take a minimal dose of Provimed, just to avoid gynecomastia.
As for mesterolone side effects, they are rare below 100mg per day. Indeed the tablets of Provimed are not alpha-alkylated 17 and do not present any harmfulness for the liver. On the other hand, if one begins to exceed 75 to 100 mg per day, one frequently sees appearing phenomena such as priapism (painful situation in which the penis after erection does not regain its normal flaccidity) in men or virilization in women.
Dosage: Take 1 tablet of 25 mg per day throughout the cure
Product performance
Anti-Estrogen: Test-Boost:
Reviews
There are no reviews yet.